GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...

An mRNA vaccine, a cousin to the COVID vaccines that blunted the pandemic, has entered human trials as a treatment for lung ...

The 2024-2025 COVID-19 vaccines are available, and the CDC recommends that certain groups get two doses, spaced six months ...

The CDC is moving toward a risk-based strategy, allowing patient input as to the frequency of COVID-19 vaccine boosters.

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...

Moderna shares rebound after six days of losses. Analysts mixed on stock with Strong Sell rating but potential for future growth.

Anyone who got sick with COVID-19 during the summer wave in South Florida has some protection against a future infection, but ...

A new framework bridges a gap in understanding RNA therapeutics by linking the structure of lipid nanoparticles to immune ...

A single COVID-19 mRNA vaccine dose provided similar protection to that conferred by a 2-dose series among immunocompetent patients aged 5 years and older.

A new vaccine that could stop people from developing the vomiting bug norovirus is on trial in the UK. The mRNA vaccine from ...

During the COVID pandemic, many of us have received multiple mRNA vaccines. New work by researchers at the VIB-UGent Center for Inflammation Research, Ghent University, and University Hospital Ghent, ...